S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
Log in

NYSE:BIO - Bio-Rad Laboratories Stock Price, Forecast & News

$362.69
+10.81 (+3.07 %)
(As of 12/12/2019 04:00 PM ET)
Today's Range
$353.04
Now: $362.69
$364.05
50-Day Range
$333.63
MA: $357.43
$374.20
52-Week Range
$220.05
Now: $362.69
$376.43
Volume265,269 shs
Average Volume221,642 shs
Market Capitalization$10.86 billion
P/E Ratio62.10
Dividend YieldN/A
Beta1.18
Bio-Rad Laboratories, Inc develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
CUSIP09057220
Phone510-724-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.29 billion
Cash Flow$6.01 per share
Book Value$134.91 per share

Profitability

Net Income$365.61 million

Miscellaneous

Employees8,260
Market Cap$10.86 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive BIO News and Ratings via Email

Sign-up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.


Bio-Rad Laboratories (NYSE:BIO) Frequently Asked Questions

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) issued its earnings results on Thursday, October, 31st. The medical research company reported $1.61 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.36 by $0.25. The medical research company earned $560.60 million during the quarter, compared to analyst estimates of $561.40 million. Bio-Rad Laboratories had a return on equity of 4.30% and a net margin of 16.14%. Bio-Rad Laboratories's revenue was up 2.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.91 EPS. View Bio-Rad Laboratories' Earnings History.

When is Bio-Rad Laboratories' next earnings date?

Bio-Rad Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Bio-Rad Laboratories.

What price target have analysts set for BIO?

3 Wall Street analysts have issued 1 year price targets for Bio-Rad Laboratories' stock. Their forecasts range from $375.00 to $400.00. On average, they anticipate Bio-Rad Laboratories' share price to reach $385.00 in the next year. This suggests a possible upside of 6.2% from the stock's current price. View Analyst Price Targets for Bio-Rad Laboratories.

What is the consensus analysts' recommendation for Bio-Rad Laboratories?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bio-Rad Laboratories.

Has Bio-Rad Laboratories been receiving favorable news coverage?

Media coverage about BIO stock has been trending somewhat negative on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bio-Rad Laboratories earned a news impact score of -1.7 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Bio-Rad Laboratories.

Are investors shorting Bio-Rad Laboratories?

Bio-Rad Laboratories saw a increase in short interest in November. As of November 29th, there was short interest totalling 758,800 shares, an increase of 51.7% from the November 14th total of 500,100 shares. Based on an average daily trading volume, of 236,400 shares, the days-to-cover ratio is currently 3.2 days. Currently, 3.6% of the shares of the stock are short sold. View Bio-Rad Laboratories' Current Options Chain.

Who are some of Bio-Rad Laboratories' key competitors?

What other stocks do shareholders of Bio-Rad Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), First Solar (FSLR), Dynavax Technologies (DVAX), Celgene (CELG), ImmunoGen (IMGN), Exelixis (EXEL) and Array Biopharma (ARRY).

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the folowing people:
  • Mr. Norman D. Schwartz, Chairman, CEO & Pres (Age 69)
  • Ms. Christine A. Tsingos, Exec. Officer (Age 60)
  • Mr. John Hertia, Exec. VP & Pres of Clinical Diagnostics Group (Age 63)
  • Mr. Michael Crowley, Exec. VP of Global Commercial Operations (Age 57)
  • Ms. Annette Tumolo, Exec. VP & Pres of Life Science Group (Age 64)

Who are Bio-Rad Laboratories' major shareholders?

Bio-Rad Laboratories' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (1.67%), Fisher Asset Management LLC (0.84%), Russell Investments Group Ltd. (0.75%), Intermede Investment Partners Ltd (0.65%), Point72 Asset Management L.P. (0.46%) and Tamarack Advisers LP (0.39%). Company insiders that own Bio-Rad Laboratories stock include Annette Tumolo, Christine A Tsingos, James R Stark, John Hertia, Michael Crowley and Timothy S Ernst. View Institutional Ownership Trends for Bio-Rad Laboratories.

Which major investors are selling Bio-Rad Laboratories stock?

BIO stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Point72 Asset Management L.P., Sector Gamma AS, First Trust Advisors LP, Roubaix Capital LLC, Eagle Asset Management Inc., Synovus Financial Corp and Gamco Investors INC. ET AL. Company insiders that have sold Bio-Rad Laboratories company stock in the last year include Christine A Tsingos, James R Stark, John Hertia, Michael Crowley and Timothy S Ernst. View Insider Buying and Selling for Bio-Rad Laboratories.

Which major investors are buying Bio-Rad Laboratories stock?

BIO stock was purchased by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, Intermede Investment Partners Ltd, Artemis Investment Management LLP, Columbus Circle Investors, Tamarack Advisers LP, California Public Employees Retirement System, Fisher Asset Management LLC and GW&K Investment Management LLC. View Insider Buying and Selling for Bio-Rad Laboratories.

How do I buy shares of Bio-Rad Laboratories?

Shares of BIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Bio-Rad Laboratories' stock price today?

One share of BIO stock can currently be purchased for approximately $362.69.

How big of a company is Bio-Rad Laboratories?

Bio-Rad Laboratories has a market capitalization of $10.86 billion and generates $2.29 billion in revenue each year. The medical research company earns $365.61 million in net income (profit) each year or $5.84 on an earnings per share basis. Bio-Rad Laboratories employs 8,260 workers across the globe.View Additional Information About Bio-Rad Laboratories.

What is Bio-Rad Laboratories' official website?

The official website for Bio-Rad Laboratories is http://www.bio-rad.com/.

How can I contact Bio-Rad Laboratories?

Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The medical research company can be reached via phone at 510-724-7000 or via email at [email protected]


MarketBeat Community Rating for Bio-Rad Laboratories (NYSE BIO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  312 (Vote Outperform)
Underperform Votes:  323 (Vote Underperform)
Total Votes:  635
MarketBeat's community ratings are surveys of what our community members think about Bio-Rad Laboratories and other stocks. Vote "Outperform" if you believe BIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel